Nasdaq confirms continued listing of Repros securities on Capital Market

NewsGuard 100/100 Score
Oct 30 2010

Repros Therapeutics Inc.® (NasdaqCM:RPRXD) today announced that it has received a letter from Nasdaq confirming that the Company has met the minimum bid price requirement for continued listing on the Nasdaq Capital Market, and Nasdaq has determined to continue the listing of the Company's securities on the Nasdaq Capital Market.

As previously announced, the Company had not been in compliance with Listing Rule 5550(a)(2) requiring the Company to maintain a minimum $1.00 bid price per share for continued inclusion on the Nasdaq Capital Market. On October 14, 2010, the Company announced that it had completed a one-for-four reverse stock split of its common stock in an effort to regain compliance with the Nasdaq continued listing requirements. The reverse stock split proved successful in the Company maintaining its listing on the Nasdaq Capital Market.

Source: Repros Therapeutics Inc.

Posted in:

Tags:

Comments (0)

Suggested Reading

Study reveals inflammation's role in long COVID's lingering effects
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
New insights into Chaga mushroom's mechanisms for fighting oral cancer
Vaccines targeting chronic diseases show promise in combatting age-related conditions
Natural killer cells lead the charge in cancer treatment innovation
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke
Non-viral gene therapy offers hope for chronic low back pain sufferers
Why use light scattering to analyze proteins and viral vectors?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions